aphranel® Named Official Partner of MXGP China 2026, Showcasing Chinese Innovation in Regenerative Aesthetics
SHANGHAI, China, September 2026 — aphranel®, the regenerative aesthetics brand of MOYOM Biotech, joined the 2026 FIM Motocross World Championship (MXGP) China Grand Prix as an Official Partner. Held from September 11–13 at the Fengxian Bay Outdoor Sports Venue in Shanghai, the event brought together international motocross teams and riders, providing a global platform to showcase Chinese innovation in medical aesthetics.
From 12 Years of Research to International Regulatory Recognition
Founded on a CaHA research programme initiated in 2013, MOYOM Biotech has dedicated over 12 years to developing regenerative biomaterials.
In February 2025, aphranel® MagiCCrystal CaHA Filler received Class III medical device approval from China's National Medical Products Administration (NMPA), becoming China's first approved CaHA microsphere facial filler.
In May 2026, aphranel® achieved another milestone when its CaHA facial filler portfolio obtained EU Medical Device Regulation (MDR) certification through BSI, supporting the brand's international expansion.
Since its Chinese market launch in May 2025, aphranel® has reported sales exceeding 200,000 syringes, with a presence across 28 provinces, 94 cities, and more than 1,000 compliant aesthetic medical institutions.
The brand's regulatory progress has also received coverage from Global Times, reflecting growing international interest in Chinese-developed medical aesthetic technologies.
aphranel® EU MDR certification and Global Times coverage.
Proprietary CaHA Technology and Complete Biodegradation
As a new-generation CaHA biostructure filler, aphranel® MagiCCrystal is developed using proprietary ACD-MT® microsphere technology and PCD-ETT® carrier gel technology.
Its CaHA microspheres measure approximately 30–35 μm and feature a distinctive raspberry-shaped, through-hole structure. These material characteristics support the product's design for immediate structural support, collagen biostimulation, and complete biodegradation.
The company reports more than 35 domestic patents, six international patents, and safety evaluations across 31 countries, reflecting its continued investment in biomaterial research and international regulatory compliance.
Beyond technology, aphranel® promotes responsible aesthetic treatment through four principles: authentic products, licensed medical institutions, qualified physicians, and compliant procedures.
Connecting Chinese Innovation with Global Motorsport
The partnership between aphranel® and MXGP reflects a shared commitment to precision, performance, innovation, and continuous improvement.
During the Shanghai event, Guangming Lin, Founder and Chairman of MOYOM Biotech, met with Zhang Xue, founder of the Chinese motorcycle brand Zhang Xue, to discuss aphranel®'s EU MDR certification and the international development of Chinese technology.
Guangming Lin shares aphranel®'s EU MDR milestone with Zhang Xue.
The collaboration brought together two different fields united by technological development and the ambition to compete on international platforms.
Advancing Chinese Regenerative Aesthetics Worldwide
Through its partnership with MXGP China 2026, aphranel® continues to strengthen international brand visibility while highlighting China's progress in regenerative biomaterial innovation.
Guided by its philosophy, The Poetics of Time, the brand remains committed to scientific research, international regulatory development, physician education, and global collaboration.
As MOYOM Biotech expands its international presence, aphranel® aims to contribute to the continued development of CaHA-based regenerative aesthetics worldwide.
